IN THE CLAIMS

1. (currently amended)A compound of formula 1 ~~the formula 1~~



(1)

~~in which~~ wherein

R^1

(i) is $-C_{1-10}$-alkyl, straight-chain or branched-chain, optionally mono- or polysubstituted by –OH, -SH, $-NH_2$, $-NHC_{1-6}$-alkyl, $-N(C_{1-6}\text{-alkyl})_2$, $-NHC_{6-14}$-aryl, $-N(C_{6-14}\text{-aryl})_2$, $-N(C_{1-6}\text{-alkyl})(C_{6-14}\text{-aryl})$, $-NO_2$, -CN, -F, -Cl, -Br, -I, $-O-C_{1-6}$-alkyl, $-O-C_{6-14}$-aryl, $-S-C_{1-6}$-alkyl, $-S-C_{6-14}$-aryl, $-SO_3H$, $-SO_2C_{1-6}$-alkyl, $-SO_2C_{6-14}$-aryl, $-OSO_2C_{1-6}$-alkyl, $-OSO_2C_{6-14}$-aryl, -COOH, $-(CO)C_{1-5}$-alkyl, $-COO-C_{1-5}$-alkyl, $-O(CO)C_{1-5}$-alkyl, by mono-, bi- or tricyclic saturated or mono- or polyunsaturated carbocycles with 3-14 ring members or/and by mono-, bi- or tricyclic saturated or mono- or polyunsaturated heterocycles with 5-15 ring members and 1-6 heteroatoms, which are preferably N, O and S,

wherein the C_{6-14}-aryl groups and the carbocyclic and heterocyclic substituents in turn may optionally be substituted one or more times by $-C_{1-6}$-alkyl, -OH, $-NH_2$, $-NHC_{1-6}$-alkyl, $-N(C_{1-6}\text{-alkyl})_2$, $-NO_2$, -CN, -F, -Cl, -Br, -I, $-O-C_{1-6}$-alkyl, $-S-C_{1-6}$-alkyl, $-SO_3H$, $-SO_2C_{1-6}$-alkyl, $-OSO_2C_{1-6}$-alkyl, -COOH, $-(CO)C_{1-5}$-alkyl, -

$COO\text{-}C_{1\text{-}5}$-alkyl or/and $-O(CO)C_{1\text{-}5}$-alkyl, and wherein the alkyl groups on the carbocyclic and heterocyclic substituents in turn may optionally be substituted one or more times by –OH, -SH, $-NH_2$, -F, -Cl, -Br, -I, $-SO_3H$ or/and –COOH, or

(ii)is $-C_{2\text{-}10}$-alkenyl, mono- or polyunsaturated, straight-chain or branched-chain, optionally mono- or polysubstituted by –OH, -SH, $-NH_2$, $-NHC_{1\text{-}6}$-alkyl, $-N(C_{1\text{-}6}\text{-alkyl})_2$, $-NHC_{6\text{-}14}$-aryl, $-N(C_{6\text{-}14}\text{-aryl})_2$, $-N(C_{1\text{-}6}\text{-alkyl})(C_{6\text{-}14}\text{-aryl})$, $-NO_2$, -CN, -F, -Cl, -Br, -I, $-O\text{-}C_{1\text{-}6}$-alkyl, $-O\text{-}C_{6\text{-}14}$-aryl, $-S\text{-}C_{1\text{-}6}$-alkyl, $-S\text{-}C_{6\text{-}14}$-aryl, $-SO_3H$, $-SO_2C_{1\text{-}6}$-alkyl, $-SO_2C_{6\text{-}14}$-aryl, $-OSO_2C_{1\text{-}6}$-alkyl, $-OSO_2C_{6\text{-}14}$-aryl, -COOH, $-(CO)C_{1\text{-}5}$-alkyl, $-COO\text{-}C_{1\text{-}5}$-alkyl, $-O(CO)C_{1\text{-}5}$-alkyl, by mono-, bi- or tricyclic saturated or mono- or polyunsaturated carbocycles with 3-14 ring members or/and by mono-, bi- or tricyclic saturated or mono- or polyunsaturated heterocycles with 5-15 ring members and 1-6 heteroatoms, which are preferably N, O and S,

wherein the $C_{6\text{-}14}$-aryl groups and the carbocyclic and heterocyclic substituents in turn may optionally be substituted one or more times by $-C_{1\text{-}6}$-alkyl, -OH, $-NH_2$, $-NHC_{1\text{-}6}$-alkyl, $-N(C_{1\text{-}6}\text{-alkyl})_2$, $-NO_2$, -CN, -F, -Cl, -Br, -I, $-O\text{-}C_{1\text{-}6}$-alkyl, $-S\text{-}C_{1\text{-}6}$-alkyl, $-SO_3H$, $-SO_2C_{1\text{-}6}$-alkyl, $-OSO_2C_{1\text{-}6}$-alkyl, -COOH, $-(CO)C_{1\text{-}5}$-alkyl, $-COO\text{-}C_{1\text{-}5}$-alkyl or/and $-O(CO)C_{1\text{-}5}$-alkyl,

and wherein the alkyl groups on the carbocyclic and heterocylic substituents in turn may optionally be substituted one or more times by –OH, -SH, $-NH_2$, -F, -Cl, -Br, -I, $-SO_3H$ or/and –COOH,

R^2 is hydrogen or $-C_{1\text{-}3}$-alkyl,

R^3, R4 and R5 are hydrogen or a hydroxyl group, wherein at least one of these substituents must be a hydroxyl group,

R^6 and R^7 may be identical or different and are hydrogen, $-C_{1\text{-}6}$-alkyl, -OH, -SH, $-NH_2$, $-NHC_{1\text{-}6}$-alkyl, $-N(C_{1\text{-}6}\text{-alkyl})_2$, $-NO_2$, -CN, $-SO_3H$, $-SO_3\text{-}C_{1\text{-}6}$-alkyl, -

COOH, -COO-C_{1-6}-alkyl, -O(CO)-C_{1-5}-alkyl, -F, -Cl, -Br, -I, -O-C_{1-6}-alkyl, -S-C_{1-6}-alkyl, -phenyl or –pyridyl, wherein the phenyl or pyridyl substituents in turn may optionally be substituted one or more times by -C_{1-3}-alkyl, -OH, -SH, -NH_2, -NHC_{1-3}-alkyl, -$N(C_{1-3}$-alkyl$)_2$, -NO_2, -CN, -SO_3H, -SO_3C_{1-3}-alkyl, -COOH, -$COOC_{1-3}$-alkyl, -F, -Cl, -Br, -I, -O-C_{1-3}-alkyl, -S-C_{1-3}-alkyl, or/and –O(CO)C_{1-3}-alkyl, and wherein the alkyl substituents in turn may optionally be substituted one or more times by –OH, -SH, -NH_2, -F, -Cl, -Br, -I, -SO_3H, -SO_3C_{1-3}-alkyl, -COOH, -$COOC_{1-3}$-alkyl, -O-C_{1-3}-alkyl, -S-C_{1-3}-alkyl or/and –O(CO)-C_{1-3}-alkyl,

or salts of the compounds of formula 1 ~~formula 1~~.

2. (currently amended) A compound as claimed in claim 1 having ~~an~~ at least one asymmetric carbon atom in the D form, the L form and D,L mixtures, and in the case of a plurality of asymmetric carbon atoms also the diastereomeric forms.

3. (currently amended) A compound as claimed in claim 1 ~~or 2~~, wherein R^2 is hydrogen or a methyl group.

4. (currently amended) A compound as claimed in claim 1 ~~one of claims 1 to 3~~, wherein R^3 = -H, R^4 = H and R^5 = -OH.

5. (currently amended) A compound as claimed in claim 1 ~~one of claims 1 to 4~~, wherein at least one of R^6 and R^7 is a halogen atom.

6. (currently amended) A compound according to claim 1 ~~as claimed in any of claims 1 to 5~~ selected from the group consisting of:

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(4-fluorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(4-chlorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2-chlorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2,4-dichlorobenzyl)-hydroxyindol-3-yl]glyoxylamide;

N-(1-oxopyridin-4-yl)-[1-(4-fluorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(4-fluorobenzyl)-4-hydroxyindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[7-hydroxy-1-(3-nitrobenzyl)-indol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[7-hydroxy-1-(2-nitrobenzyl)-indol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2,6-difluorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-(7-hydroxy-1-isobutylindol-3-yl)glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-(1-cyclopropyl-methyl-7-hydroxyindol-3-yl)glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[7-hydroxy-1-(4-hydroxybenzyl)-indol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-N-methyl-[1-(4-fluorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(4-fluorobenzyl)-6-hydroxyindol-3-yl]glyoxylamide;

N-(1-oxopyridin-4-yl)-[1-(2-chlorobenzyl)-6-hydroxyindol-3-yl]glyoxylamide;

and physiologically tolerated salts thereof.

7. (currently amended) The ~~A~~ compound according to claim 1 ~~as claimed in any of claims 1 to 6 selected from:~~ that is

N-(3,5-Dichloro-1-oxopyridin-4-yl)-[1-(2,6-difluorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide and physiologically tolerated salts thereof.

8. currently amended) A process for preparing a compound ~~compounds~~ of claim 1, comprising ~~formula 1, which comprises~~ converting N-(pyridine-4-yl)-indol-3-ylglyoxylamides of formula 2



(2)

~~formula 2~~ into the analogous N-(1-oxopyridin-4-yl)-indol-3-ylglyoxylamides of formula 1 ~~formula 1~~ by treatment with an oxidizing agent, and forming ~~liberating~~ the compound ~~compounds of formula 1~~ by eliminating a protective group.

9. (currently amended) The process as claimed in claim 8, said oxidizing agent is selected from the group consisting of ~~wherein~~ a peracid and a ~~peracid, in particular m-chloroperbenzoic acid or/and~~ peracetic acid ~~acid, is used as oxidizing agent~~.

10. (currently amended) A method of treating ~~The use of the compounds of formula 1 as claimed in any of claims 1 to 6 as therapeutic active ingredients for producing drug products for the treatment of~~ disorders in which inhibition of phosphodiesterase 4 is therapeutically beneficial comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1.

11. (currently amended) A method of treating ~~The use of the compounds of formula 1 as claimed in any of claims 1 to 6 as therapeutic active ingredients for producing drug products for the treatment of~~ disorders associated with the effect of eosinophils comprising administering a therapeutically effective amount of a compound of claim 1 to a patient in need thereof.

12. (currently amended) A method of treating ~~The use of the compounds of formula 1 as claimed in any of claims 1 to 6 as therapeutic active ingredients for producing drug products for the treatment of~~ disorders associated with the effect of neutrophils comprising administering a therapeutically effective amount of a compound of claim 1 to a patient in need thereof.

13. (currently amended) A method of treating a ~~The use of the compounds of formula 1 as claimed in any of claims 1 to 6 as therapeutic active~~

~~ingredients for producing drug products for the treatment of~~ hyperproliferative disorder comprising administering a therapeutically effective amount of a compound of claim 1 to a patient in need thereof to treat the hyperproliferative disorder ~~disorders~~.

14. (currently amended) A drug product comprising a compound of claim 1 and a ~~one or more compounds as claimed in any of claims 1 to 6 in addition to~~ conventional physiologically tolerated carrier, diluent and excipient ~~carriers and/or diluents and excipients~~.

15. (currently amended) A process for producing a drug product ~~as claimed in claim 14,~~ comprising admixing a compound of claim 1 with a ~~which comprises one or more compounds as claimed in any of claims 1 to 6 being processed with~~ conventional pharmaceutical carrier, diluent or excipien to form the drug product ~~carriers and/or diluents and other excipients to pharmaceutical preparations, or being converted into a form which can be used therapeutically~~.

16. (currently amended) A pharmaceutical composition comprising a compound according to claim 1 and at least one additional ~~The use of compounds of the general formula 1 as claimed in any of claims 1 to 6 and/or of drug products as claimed in claim 14 alone or in combination with one another or in combination with other~~ active pharmaceutical agent ~~ingredients~~.

17. (new) The process as claimed in claim 8, said oxidizing agent is m-chloroperbenzoic acid.